J Breast Cancer. 2019 Jun;22(2):196-209 https://doi.org/10.4048/jbc.2019.22.e23 pISSN 1738-6756·eISSN 2092-9900 Original Article Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer Jian Gao 1,2, Fusheng Deng 2, Weidong Jia 3 1Department of Clinical Medicine, Clinical Medical College of Shandong University, Jinan, China 2Department of General Surgery, the First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China 3Department of Hepatic Surgery, the First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China Received: Dec 11, 2018 ABSTRACT Accepted: Apr 12, 2019 Correspondence to Purpose: Breast cancer has become a major public health threat in the current society. Weidong Jia Anthracycline doxorubicin (DOX) is a widely used drug in breast cancer chemotherapy. We Department of Hepatic Surgery, the First aimed to investigate the immunogenic death of breast tumor cells caused by DOX, and detect the Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences effects of combination of DOX and a small molecule inhibitor in tumor engrafted mouse model. and Medicine, University of Science and Methods: We used 4T1 breast cancer cells to examine the anthracycline DOX-mediated Technology of China, Hefei 230001, China. immunogenic death of breast tumor cells by assessing the calreticulin exposure and E-mail:
[email protected] adenosine triphosphate and high mobility group box 1 release.